Package Leaflet: Information for the User
Xariva 15 mg hard capsules EFG
Xariva 20 mg hard capsules EFG
rivaroxaban
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Xariva contains the active substance rivaroxaban and is used in adults to:
Xariva is used in children and adolescents under 18 years of age and with a body weight of 30 kg or more to:
This medicine belongs to a group of medicines called antithrombotic agents. It works by blocking a factor in the blood clotting process (factor Xa) and thus reducing the tendency of the blood to form clots.
Do not takeXariva
Do not take Xariva and inform your doctorif any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting this medicine.
Be particularly careful withXariva
Inform your doctor if you have any of these conditionsbefore taking this medicine. Your doctor will decide if you should be treated with this medicine and if you should be kept under closer observation.
If you need surgery
Children and adolescents
This medicine is not recommended in children with a body weight below 30 kg.There is not enough information about the use of rivaroxaban in children and adolescents for the indications in adults.
Other medicines and Xariva
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.
If any of the above circumstances apply to you, inform your doctorbefore taking this medicine, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medicine and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you also use a preventive treatment.
If you take:
If any of the above circumstances apply to you, inform your doctorbefore taking this medicine, as the effect of rivaroxaban may be reduced. Your doctor will decide if you should be treated with this medicine and if you should be kept under closer observation.
Pregnancy andbreastfeeding
Do not take rivaroxaban if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking rivaroxaban, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban may cause dizziness (a common side effect) or fainting (an uncommon side effect) (see section 4, "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
Xariva contains lactose and sodium
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per capsule; this is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
You must take Xariva with food.
Swallow the capsules, preferably with water.
If you have difficulty swallowing the capsule whole, consult your doctor about other ways to take rivaroxaban. The contents of the capsule can be mixed with water or apple sauce immediately before taking it. Then take food.
If necessary, your doctor may also administer the contents of the capsule of this medicine dissolved through a gastric tube.
What dose to take
The recommended dose is one rivaroxaban 20 mg capsule once a day.
If you have kidney problems, the dose may be reduced to one rivaroxaban 15 mg capsule once a day.
If you need to undergo a procedure to treat blocked blood vessels in your heart (called percutaneous coronary intervention - PCI with stent insertion), there is limited evidence to reduce the dose to one rivaroxaban 15 mg capsule once a day (or to one rivaroxaban 10 mg capsule once a day if your kidneys do not function properly) in addition to an antiplatelet medicine such as clopidogrel.
The recommended dose is one rivaroxaban 15 mg capsule twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one rivaroxaban 20 mg capsule once a day.
After at least 6 months of treatment for blood clots, your doctor may decide to continue treatment with one 10 mg capsule once a day or one 20 mg capsule once a day.
If you have kidney problems and are taking one rivaroxaban 20 mg capsule once a day, your doctor may decide to reduce the treatment dose to one rivaroxaban 15 mg capsule once a day after 3 weeks if the risk of bleeding is higher than the risk of having another blood clot.
The dose of rivaroxaban depends on body weight and will be calculated by the doctor.
The recommended dose for children and adolescents with a body weight between 30 kg and less than 50 kgis one rivaroxaban 15 mgcapsule once a day.
The recommended dose for children and adolescents with a body weight of 50 kgor more is one rivaroxaban 20 mgcapsule once a day.
Take each dose of rivaroxaban with a drink (e.g. water or juice) during a meal. Take the capsules every day at approximately the same time. Consider setting an alarm to remind you.
For parents or caregivers: observe the child to ensure they take the entire dose.
Since the dose of rivaroxaban is based on body weight, it is important to attend scheduled visits with the doctor, as it may be necessary to adjust the dose as weight changes.
Never adjust the dose of Xariva on your own. Your doctor will adjust the dose if necessary.
If a lower dose is required, please use an alternative presentation of rivaroxaban granules for oral suspension.
In children or adolescents who cannot swallow the capsule whole, rivaroxaban granules for oral suspension can be used. If the oral suspension is not available, the contents of the rivaroxaban capsule can be mixed with water or apple sauce immediately before taking it. Take some food after taking this mixture. If necessary, your doctor may also administer the contents of the capsule through a gastric tube.
If you spit out the dose or vomit
Call your doctor if you spit out the dose or vomit repeatedly after taking this medicine.
When to take Xariva
Take this medicine every day, until your doctor tells you to stop.
Try to take the dose at the same time every day to remember when you should take it.
Your doctor will decide how long you should continue taking the treatment.
To prevent the formation of blood clots in the brain (stroke) or in other blood vessels:
If it is necessary to normalize your heartbeat through a procedure called cardioversion, take rivaroxaban at the times indicated by your doctor.
If you take more Xariva than you should
Call your doctor immediatelyif you have taken too many rivaroxaban capsules. Taking too much rivaroxaban increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Xariva
If you are taking one 20 mg or one 15 mg capsule once a day and you forget to take a dose, take it as soon as you remember. Do not takemore than one capsule in one day to make up for a forgotten dose. Take the next dose the next day and then continue taking one capsule every day.
If you are taking one 15 mg capsule twice a day and you forget to take a dose, take it as soon as you remember. Do not takemore than two 15 mg capsules in one day. If you forget to take a dose, you can take two 15 mg capsules at the same time, for a total of two capsules (30 mg) in one day. The next day, you should continue taking one 15 mg capsule twice a day.
If you stop takingXariva
Do not stop taking rivaroxaban without talking to your doctor first, as rivaroxaban treats and prevents serious conditions.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Like other similar medicines to reduce blood clot formation, rivaroxaban can cause bleeding that can endanger the patient's life. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Tell your doctor immediately if you experience any of the following symptoms:
Your doctor may decide to keep you under closer observation or change your treatment.
The frequency of these adverse effects is very rare (up to 1 in 10,000 people).
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible adverse effects found in adults, children, and adolescents
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very Rare(may affect up to 1 in 10,000 people)
Frequency not known(frequency cannot be estimated from available data)
Adverse effects in children and adolescents
In general, the adverse effects observed in children and adolescents treated with rivaroxaban were similar to those observed in adults and their severity was mainly mild to moderate.
Adverse effects that were more frequently observed in children and adolescents:
Very frequent(may affect more than 1 in 10 people)
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on each blister after "CAD" or "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Xariva 15 mg:
Each capsule contains 15 mg of rivaroxaban.
Capsule content:lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, hypromellose, sodium lauryl sulfate, and magnesium stearate;
Capsule shell:gelatin, titanium dioxide (E-171), red iron oxide (E-172), yellow iron oxide (E-172), and black iron oxide (E-172).
Composition of Xariva 20 mg:
Each capsule contains 20 mg of rivaroxaban.
Capsule content:lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, hypromellose, sodium lauryl sulfate, and magnesium stearate;
Capsule shell:gelatin, titanium dioxide (E-171), yellow iron oxide (E-172), red iron oxide (E-172), and black iron oxide (E-172).
Appearance of the product and package contents
Dose of 15 mg: the hard capsules of Xariva 15 mg are 19.4 mm long (size "1") with opaque light brown cap and body.
Xariva 15 mg is presented in packages of 28 hard capsules in PVC/PVdC - aluminum blister.
Dose of 20 mg: the capsules of Xariva 20 mg are 21.7 mm long (size "0") with opaque dark brown cap and body.
Xariva 20 mg is presented in packages of 28 hard capsules in PVC/PVdC - aluminum blister.
Marketing authorization holder
Kern Pharma, S.L.
Venus, 72 - Pol. Ind. Colón II
08228 Terrassa, Barcelona
Spain
Manufacturer
Zentiva, S.A.
B-dul Theodor Pallady nr.50, sector 3,
Bucharest, 032266,
Romania
or
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park,
Paola, PLA3000,
Malta
Date of the last revision of this prospectus:May 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es